Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose

Michael P. O’Leary1, Audrey H. Choi1, Sang-In Kim1, Shyambabu Chaurasiya1, Jianming Lu1, Anthony K. Park1, Yanghee Woo1, Susanne G. Warner1, Yuman Fong1,2 and Nanhai G. Chen1,2,3*

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) has been increasing by 0.5% per year in the United States. PDAC portends a dismal prognosis and novel therapies are needed. This study describes the generation and characterization of a novel oncolytic chimeric orthopoxvirus for the treatment of pancreatic cancer.

Methods: After chimerization and high-throughput screening, CF33 was chosen from 100 new chimeric orthopoxvirus isolates for its ability to kill pancreatic cancer cells. In vitro cytotoxicity was assayed in six pancreatic cancer cell lines. In vivo efficacy and toxicity were evaluated in PANC-1 and MIA PaCa-2 xenograft models.

Results: CF33 caused rapid killing of six pancreatic cancer cell lines in vitro, releasing damage-associated molecular patterns, and regression of PANC-1 injected and non-injected distant xenografts in vivo after a single low intratumoral dose of 10^7 plaque-forming units. Using luciferase imaging, CF33 was noted to preferentially replicate in tumors which corresponds to the low viral titers found in solid organs.

Conclusion: The low dose of CF33 required to treat pancreatic cancer in this preclinical study may ease the manufacturing and dosing challenges currently facing oncolytic viral therapy.

Keywords: Cancer therapy, Immunotherapy, Translational, Vaccinia, Viral vectors

Background

New cases of pancreatic ductal adenocarcinoma (PDAC) have been increasing by 0.5% per year in the United States and a dismal mortality rate persists. Currently, PDAC is the fourth leading cause of cancer-related death and is anticipated to be the second leading cause in the United States by 2030. Cancer-related 5-year survival from 1975 to 2008 has had an overall survival increase from 49 to 68%, however, PDAC survival has only increased from 2 to 6% [1]. Surgical resection is the mainstay of curative treatment but as many as 80% of patients present with unresectable regionally advanced or metastatic disease at the time of diagnosis [1]. In the setting of metastatic disease, recent trials using FOLFIRINOX resulted in an incremental improvement of overall survival to 11.1 months compared to 6.8 months seen with gemcitabine [2]. Thus, PDAC will continue to portend a dismal prognosis unless novel therapies are introduced.

Immmuno-oncolytic therapy is an exciting area of current cancer research. An enriched understanding of tumor biology and patient immunology has led to the development of the current generation of oncolytic viruses (OVs). Orthopoxviruses, such as vaccinia virus (VACV), have been investigated for their tumoricidal potential in numerous cancers, including pancreatic cancer [3–5]. Characteristics of these viruses that made them favorable candidates as clinical agents include...
cytoplasmic replication, the excellent safety profile in the global eradication of smallpox, and a short life cycle [6–8]. Clinical trials data from a number of these agents have confirmed a favorable toxicity profile. However, the field would benefit from viruses that are more potent in cancer killing, and that cost less to produce.

The novel oncolytic virus presented in the current study is CF33. It is a chimeric orthopoxvirus selected in a high throughput screen for its efficient viral proliferation and tumoricidal capabilities. In the following studies, we demonstrate the potent ability of this virus and its imaging capable derivative CF33-Fluc, to replicate in and kill a panel of pancreatic cancer cells in vitro. In vivo models of pancreatic cancer xenografts in nude mice were then used to demonstrate the selectivity of this virus for cancer while sparing normal tissues, and to demonstrate the safety of this virus in preclinical models. We also show that treatment of tumors by direct tumor injection can not only produce tumor regression of the injected tumor but also lead to viral spread to distant non-injected tumors and distant tumor regression.

**Methods**

**Cell lines and maintenance**

African green monkey kidney fibroblasts (CV-1) were purchased from the American Type Culture Collection (ATCC). CV-1 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic–antimycotic solution. Human pancreatic cancer cell lines PANC-1, MIA PaCa-2, BxPC-3, SU.86.86 and AsPC-1 were purchased from ATCC. Capan-1 was a kind gift from Dr. T. Ku's lab (City of Hope, Duarte, CA, USA). All pancreatic cancer cell lines were cultured in Roswell Park Memorial Institute medium (RPMI) 1640 supplemented with 10% FBS and 1% antibiotic–antimycotic solution. Media and supplements were purchased from Corning (Corning, NY). All cells were maintained in a humidified incubator at 37 °C and 5% CO2. Cell lines were authenticated by Genetica® DNA Laboratories.

**Viruses**

Cowpox virus strain Brighton, raccoonpox virus strain Herman, rabbitpox virus strain Utrecht, VACV strains Western Reserve, International Health Department, Elstree, CL, Lederle-Chorioallantoic (LC) and AS were purchased from ATCC. CV-1 cells were used for both amplification and titration of these orthopoxviruses.

**Chimerization of orthopoxviruses and high-throughput screening**

Chimerization of orthopoxviruses was achieved by co-infecting CV-1 cells with all the aforementioned strains of orthopoxvirus. Following the co-infection, one hundred individual plaques were picked and subjected to a total of three rounds of plaque purification in CV-1 cells to obtain 100 clonally purified chimeric orthopoxviruses. High-throughput screening was used to compare the cytotoxic efficacy of these chimeric clones and the parental strains against the NCI-60 panel. CF33 was selected as the chimeric isolate that demonstrated superior cell killing in the NCI-60 panel when compared to all parental viruses and other plaque-purified isolates.

**Generation of recombinant chimeric orthopoxvirus expressing firefly luciferase**

To construct thymidine kinase (TK) shuttle vector, the left and right flanking sequences of the TK gene were PCR-amplified from CF33 genomic DNA using Q5 High-Fidelity 2X Master Mix (New England Biolabs Inc., Ipswich, MA) and the primers: 5’-GGCAGGATTATC GATGGAATTACGTTAACCTCGTCTAATTAATTCGTAC-3’ (left flank), 5’-CAGGTCGATAAGTCA GAATTTAGCCGAGTT AAACGGAC CGTCGACCGATCCCGTACGCCCG CGGAGG TAATGATATGTAATACGGTGTCGAG GGT AACATGC-3’ and 5’-GGCGGATTCGTAATATCTTCTGA AAT CCGCCGTACTAGG-3’ (right flank). The two fragments were joined together using the method of gene splicing by overlapping extension [9]. The resulting fragment was digested with Ndel and EcoRI and cloned into plasmid pGPT to yield p33NC-TK. The flanking sequences of TK in the shuttle vector were confirmed by sequencing. p33NC-TK contains the left and right flanking sequences of TK separated by Saci, SalI, BamHI, Nhel and NotI, and *Escherichia coli* guanine phosphoribosyltransferase (gpt) gene driven by the VACV early promoter p7.5E as a transient dominant selectable marker.

The Emerald expression cassette with the VACV H5 early/late promoter was PCR-amplified from the plasmid Emerald-pBAD (Addgene, Cambridge, MA) using Q5 High-Fidelity 2X Master Mix (New England Biolabs Inc., Ipswich, MA) and the primers: 5’-GGCAGGATTACGTTAG CTCAAAAATGAATAATACAAAGGTTCTTG AGG GTTGTGTTAATTGAAGCGGAGAAATAC CTAAATTAGTCGACCATCCATGGTAGCAAGGCG AGGAGCGTTTCACC-3’ and 5’-GGCGGATCCATA AAAAAATATTATACGATACGGCC CGAGGTGATC-3’. The PCR fragment was digested with Saci and BamHI and cloned into plasmid p33NC-TK to yield p33NCTK-H5-Emerald. The sequence of the Emerald expression cassette was confirmed by sequencing. To generate a shuttle vector containing the firefly luciferase expression cassette with the VACV H5 promoter, the firefly luciferase cDNA was PCR-amplified from the plasmid pCDNA3.1(+)/Luc2 = tdT (Addgene, Cambridge,
MA) using Q5 High-Fidelity 2X Master Mix (New England Biolabs Inc., Ipswich, MA) and the primers: 5'-GCGGTCGACCCAGGTAGATGCAGGTTATTACG and 5'-CGGGGATCCATAAAATTTAACGCGCATCATTGACCAAGAAGGCCCAGC3' and 5'-GGGGGATCCATAAAATTTAACGCGCATCATTGACCAAGAAGGCCCAGC-3'. The PCR fragment was digested with *SalI* and *BamHI* and cloned into the same-cutter p33NCTK-H5-Emerald replacing Emerald to yield p33NCTK-H5-Fluc2. The sequence of the firefly luciferase cDNA was confirmed by sequencing.

CV-1 cells were infected with CF33 at a multiplicity of infection (MOI) of 0.1 for 1 h and then transfected with p33NCTK-H5-Fluc2 by use of jetPRIME in vitro DNA & siRNA transfection reagent (Polyplus-transfection Inc., New York, NY). Two days post infection, infected/transfected cells were harvested and the recombinant viruses were selected and plaque purified as described previously [10].

**Cytotoxicity and viral proliferation assays**

PANC-1, MIA PaCa-2, BxPC-3, SU.86.86, AsPC-1 and Capan-1 were seeded in 96 well plates (3 × 10³ cells per well) and infected with CF33 or CF33-Fluc at MOIs 1, 0.1, 0.01 in triplicate. A daily cell viability assay was performed by adding 20 μL of CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI) to all wells. Absorbance was measured after 1 h of incubation at 495 nm using a plate reader for 8 days (Tecan, Männedorf, Switzerland). Experimental results were standardized to a media only and mock-infected control in each cell line. This experiment was repeated to ensure validity. The ability of CF33-Fluc to replicate in PANC-1, MIA PaCa-2, BxPC-3, SU.86.86, AsPC-1 and Capan-1 was evaluated by a previously described viral growth assay at an MOI of 0.01 for time points 24, 48, and 72 h in duplicate and repeated [11].

**Flow cytometry**

PANC-1 and MIA PaCa-2 cells were seeded in 6-well plates and infected next day with CF33 at an MOI of 5 or mock-infected with the virus diluent. Sixteen hours post-infection, the cells were harvested using 5 mM EDTA and washed three times with PBS. Cells were then stained with Alexafluor-488 conjugated anti-calreticulin antibody (ab196158; Abcam, Cambridge, MA) or an isotype antibody (ab199091; Abcam, Cambridge, MA) for 1 h. Stained cells were washed three times with FACS buffer, fixed with 4% paraformaldehyde and analyzed on a BD Accuri C6 flow cytometer.

**ATP assays**

PANC-1 and MIA PaCa-2 cells were seeded in 6-well plates and infected next day with CF33 at an MOI of 5. Sixteen hours post-infection, supernatants were collected and ATP concentration was measured by the ATP Determination kit (Cat# A22066; Invitrogen, Carlsbad, CA) following manufacturer’s instructions.

**Western blot analysis of high-mobility group box 1 (HMGB1) protein**

PANC-1 and MIA PaCa-2 cells were seeded in 6-well plates and infected next day with CF33 at an MOI of 5. Supernatants were collected from infected wells at the indicated time points and concentrated using a column with 3 kDa size cutoff. The concentrated supernatants were loaded (25 μL/well) and ran on a 12% SDS-PAGE. HMGB1 was detected using a rabbit anti-HMGB1 antibody (Cat# ab18256; Abcam, Cambridge, MA) at 1:500 dilution followed by an HRP-labeled goat anti-rabbit secondary antibody (Cat# ab205718; Abcam Cambridge, MA) at 1:5000 dilution.

**Treatment of PANC-1 and MIA PaCa-2 flank xenografts with CF33 and CF33-Fluc**

All animal studies were conducted under a City of Hope Institutional Animal Care and Use Committee (IACUC)-approved protocol (IACUC #15003). Forty-one 6-week old Hsd:Athymic Nude-Foxn1nu female mice (Envigo, Indianapolis, IN) were purchased, acclimatized and bilateral flank tumors were generated by injecting 1.25 × 10⁶ PANC-1 (per injection site) in 100 μL PBS containing 50% matrigel. Mice were grouped into three well-matched groups based on their tumor size: PBS injected alone (n = 6), 10³ plaque-forming units (PFU) of CF33 (n = 6), or 10⁴ PFU of CF33-Fluc (n = 17). A left-sided intratumoral injection was given when volume of left tumor reached 240 mm³ in each mouse. A tenfold higher dose was given in the CF33-Fluc group to ensure visualization on luciferase imaging. Two mice in the PBS group and four mice from the CF33-Fluc treatment group were euthanized on days 3, 13 and 27. Bilateral tumors and organs (heart, lung, liver, spleen, kidney, ovary, brain) were harvested. Tissues were divided into two halves, one half was snap frozen for the purpose of virus titration and the other half was formalin-fixed for immunohistochemical analysis. The remaining mice were euthanized on day 49. In a separate experiment, 8 mice were implanted with 2 × 10⁶ MIA PaCa-2 cells to obtain bilateral flank tumors as described for the PANC-1 model. Mice received a left sided intratumoral injection of PBS alone (n = 3) or 10⁵ PFU of CF33 (n = 5) in 50 μL PBS when tumor volume reached 400 mm³. All MIA PaCa-2 xenograft-bearing mice were euthanized at the termination of the experiment on day 43.

For the evaluation of anti-tumor efficacy, tumors were measured twice weekly and tumor volume was calculated
using $V = \frac{1}{2} \times A^2 \times B$ where $A$ is the shortest and $B$ is the longest diameter. Percent tumor change was calculated from the date of intervention. Virus shedding was determined by performing standard plaque assays on urine, stool and blood samples. Stool and urine from four PANC-1 bearing mice, injected with $10^3$ PFU of CF33-Fluc, was collected twice per week for 1 month post-treatment and blood was collected at the time of euthanasia.

**Luciferase imaging**

Firefly luciferin solution was prepared by dissolving 1 g of XenoLight d-luciferin—K⁺ Salt Bioluminescent Substrate (PerkinElmer, Waltham, MA) in 35 mL of PBS. Intraperitoneal delivery was performed in a control mouse and all mice injected with CF33-Fluc and the mice were imaged using Lago X optical imaging system (Spectral Instruments Imaging, Tucson, AZ) after 7 min. Luciferase imaging was performed twice weekly and prior to animal euthanasia.

**Immunohistochemical analysis**

Harvested tumors were fixed in formalin for 48 h, paraffin embedded and 5 µm thick sections were obtained. Standard hematoxylin and eosin (H&E) staining was performed. On adjacent tumor sections, immunohistochemical staining was performed. The IHC sections were deparaffinized followed by heat-mediated antigen-retrieval. Briefly, for antigen-retrieval tumor sections were hydrated and steamed for 40 min in IHC-TEK Epitope Retrieval Solution (IHC World, Ellicott City, MD). Following antigen-retrieval, tumor sections were permeabilized with methanol and were blocked using TNB Blocking buffer (PerkinElmer, Waltham, MA) for 20 min. The sections were then incubated with rabbit anti-vaccinia virus antibody diluted 1:100 in TNB blocking buffer (Cat# ab35219; Abcam, Cambridge, MA), overnight in a humidified chamber at 4 °C. The following day, tumor sections were washed and incubated with Alexa Fluor-488-conjugated goat anti-rabbit (Cat# ab150077, Abcam, Cambridge, MA) for 1 h at room temperature. Finally, the sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) and were imaged using EVOS FL Auto Imaging System (Thermo Fisher Scientific, Waltham, MA).

**Statistical analysis**

Statistical analysis was performed using GraphPad Prism (Version 7.01, La Jolla, CA). Comparisons were performed using Student’s t test or one-way ANOVA, when appropriate. Correlation was performed using Pearson’s correlation formula. Logistic or exponential regression line fitting was performed where appropriate. $p$ values $<0.05$ were considered significant.

**Results**

**Chimerization of orthopoxviruses and high-throughput screening**

A pool of chimeric orthopoxviruses was generated by co-infecting CV-1 cells with cowpox virus strain Brighton, raccoonpox virus strain Herman, rabbitpox virus strain Utrecht, and VACV strains WR, IHD, Elstree, CL, Lederle-Chorioallantoic and AS at an MOI of 0.01 per virus. Our pilot experiments indicate that CV-1 cells are susceptible to all the orthopoxviruses used in this study. One hundred chimeric orthopoxvirus plaques were picked from CV-1 cells infected with the chimeric orthopoxvirus pool. These 100 plaques were further plaque-purified two more times to yield 100 clonally purified individual chimeric virus isolates.

Tumor cell-killing activity of 100 chimeric orthopoxvirus isolates, together with nine parental virus strains were evaluated and compared in a panel of the NCI-60 cell lines. Each cell line was infected with each virus at an MOI of 0.01. Cell viability was measured at 96 h post infection using MTS assays. The MOI in this high throughput screening experiment was intentionally kept low, and optimized to compare cell killing in adherent cell lines (the majority of cell lines in the NCI-60 panel are adherent cells) so potent new virus isolates can stand out. This amount of virus, however, was too low to see any significant and consistent cell killing in suspension cell lines. Therefore, the results from six leukemia cell lines were not included in the analysis for the purpose of virus comparison. Among 100 new chimeric orthopoxvirus isolates, isolates CF17 and CF33 demonstrated significantly better cell killing ($p < 0.001$) in the NCI-60 solid tumor cell lines than all nine parental orthopoxvirus strains (Fig. 1), indicating that virus chimerisation can generate a backbone virus that is better than its parental viruses. Both CF17 and CF33 caused significant cell death in the majority of the NCI-60 solid cancer cell lines even at the low MOI of 0.01. CF33 was chosen for further study.

Initial genomic sequence analysis of CF33 revealed that the overall sequence matched more closely to VACV genomes. However, in the absence of published sequences for four out of the nine parental viruses (VACV strains IHD, CL, Lederle-Chorioallantoic and AS), we are not able to pinpoint which parts of CF33 came from which parental viruses. Compared to the genomic sequence of VACV strain WR, CF33 contains multiple insertions, deletions and numerous point mutations throughout its genome, thus, it is impossible at this time to pinpoint what sequence variations make the CF33
virus superior to the parental viruses. In future, we plan to perform in-depth sequence analysis for better understanding of the mechanisms through which CF33 outperforms its parental viruses.

**CF33-Fluc infects, replicates in, and kills human pancreatic cancer cell lines in a dose-dependent manner in vitro**

Both CF33 and CF33-Fluc killed all 6 pancreatic cell lines tested in vitro in a dose-dependent manner. Figure 2a–c shows the dose-dependent cancer cell death from CF33-Fluc across all cancer cells tested. Notably, less than 50% pancreatic cancer cell survival occurred across all cell lines at an MOI of 1 by 72 h post-infection. Even at lower MOIs, efficient cell killing was noted in all cell lines. All cell lines, except MIA PaCa-2 and Capan-1, had less than 10% survival by 96 h post-infection at MOI 0.01. Most pronounced increases in PFU/million cells were noted in BxPC-3 and PANc-1 cell lines with an approximate 10⁴ fold increase of CF33-Fluc by 2 days post-infection. A correlation of the lethal dose for 50% cell kill (LD50) at 72 h and viral proliferation at 24 h was observed in PANc-1, SU.86.86, AsPC-1, and Capan-1 (R² = 0.932, Fig. 2d).

**CF33 induces immunogenic cell death (ICD) in pancreatic cancer cells**

Besides direct cell lysis, OVs are known to elicit potent anti-tumoral immune responses, mainly through release of tumor-associated antigens and ICD-related damage-associated molecular patterns (DAMPs) [12]. Calreticulin (CRT), ATP and HMGB1 are critical DAMPs in ICD. Surface-exposed CRT serves as an “eat me” signal for macrophages, neutrophils, and dendritic cells (DCs), whereas ATP acts as a “find me” signal for macrophages and DC precursors. HMGB1 promotes production of cytokines and antigen cross-presentation. Figure 3a shows that infection with CF33 resulted in a five or two-fold increase in cell surface-exposed CRT in PANc-1 cells and MIA PaCa-2 cells at 16 h post infection, respectively. At the same time, the release of ATP by infected PANc-1 and MIA PaCa-2 was also significantly increased compared to mock-infected cells (Fig. 3b). The release of HMGB1 became detectable at 48 h post infection for both PANc-1 cells and MIA PaCa-2 cells (Fig. 3c). These results suggested that CF33-induced cell death could be highly immunogenic.

**Low dose of CF33 causes tumor regression without toxicity in PANc-1 and MIA PaCa-2 models in vivo**

Significant regression was noted in xenografts injected with intratumoral CF33 at 10³ PFU in PANc-1 and 10⁵ PFU in MIA PaCa-2 when compared to PBS injected control (p = 0.0001 and p = 0.01, respectively, Fig. 4a, b). Toxicity to CF33 and CF33-Fluc was determined by net weight loss. No toxicity was noted in the PANc-1 group injected with a dose of 10³ PFU of CF33 or the attenuated CF33-Fluc at 10⁴ PFU when compared to the PBS-injected group (p = 0.25, p = 0.68, respectively, Fig. 4d). PANc-1 bearing mice had no detectable CF33 or CF33-Fluc in the stool, urine or blood at any point of collection.

**CF33-Fluc luciferase activity correlates with tumor regression and spreads to non-injected, distant xenografts in PANc-1**

Luciferase signal was noted in the injected tumors at the earliest measured time point of 1 day post-injection (Fig. 5a–c). Decrease in luciferase relative units correlated significantly with percent regression of injected tumor size (R² = 0.879, Fig. 5b). The right sided, or non-injected, distant tumor showed significant regression when compared to the PBS control tumor in both CF33 and CF33-Fluc groups (p = 0.006 and 0.007, respectively, Fig. 4c). Attenuation of the virus did not affect tumor regression in the non-injected tumor as no difference was noted when comparing CF33 or CF33-Fluc (p = 0.99). Luciferase signal was noted in the non-injected tumors after 8 days of treatment and luciferase activity increased.
in the non-injected tumors for the remainder of the experiment (Fig. 5a, c).

**CF33-Fluc selectively preferentially replicates in PANC-1 xenografts**

High CF33-Fluc titers were noted in the injected tumors at 3 days post-treatment (Fig. 5d). Titers above $10^7$ PFU/g tissue were seen in the injected tumors on days 3 and 13. On day 27, the highest titer was noted at $10^8$ PFU/g of injected tumors. The non-injected, distant tumors showed a serial increase in CF33-Fluc titers from $10^3$ PFU/g tissue at day 3 to nearly $10^8$ PFU/g tissue by day 27, which correlated to the increase in luciferase relative units ($R^2 = 0.9972$). CF33-Fluc was found in other organs (Fig. 5d). Notably, organs contained at least $10^3$–$10^4$ times fewer viruses than the injected tumors. The limit of detection was dependent on organ weight and ranged from $1.2 \times 10^2$ to $1.1 \times 10^3$ PFU/g.

Histology and immunohistochemistry shows tumor cell killing and migration of virus from injected to non-injected, distant tumors

H&E and DAPI fluorescence on sections of the control tumor over time show overgrowth of PANC-1 cells and confirm no viral green fluorescent staining (Fig. 6a). Infection of CF33-Fluc was confirmed at day 3 in the injected tumors through anti-viral green fluorescent staining. H&E shows early signs of tumor necrosis and confirms the presence of virus in only the injected tumor (Fig. 6b). By day 27, H&E showed nearly complete central tumor necrosis in the injected tumor when compared to control and IHC confirmed vaccinia virus in
the non-injected, distant tumor. This is consistent with the findings from the luciferase imaging and tumor viral titers.

**Discussion**

Pancreatic ductal adenocarcinoma portends a dismal prognosis. Less than 20% of patients are candidates for surgical intervention [13] and of those who are resected, over 80% will ultimately succumb to recurrent disease [14].Current combination chemotherapeutics in metastatic PDAC have resulted in survival benefits measured in months in the setting of advanced disease [2, 15]. New modalities to treat patients diagnosed with pancreatic cancer are needed. In this paper, we describe the creation and selection of a promising new oncolytic virus CF33. Data supporting CF33 as a potent anti-cancer agent are presented.

Oncolytic viruses are a promising emerging therapy. These viruses selectively infect, replicate in and kill cancer cells. Presently, they are being used in clinical trials to target over 20 types of cancers [16]. Remarkable progress has been made with the first OV, herpes simplex virus 1 (HSV-1) talimogene laherparepvec (T-VEC, Amgen Inc. Thousand Oaks, CA, USA), now approved by the Food and Drug Administration (FDA) after a Phase III trial demonstrated improved response rates in advanced melanoma [17]. Benefits of OVs include tolerable safety profiles that can be further enhanced by virulence gene attenuation [18, 19]. Another benefit is arming the OV to express proteins to enhance the anti-tumor response [20, 21].

Numerous oncolytic viruses have been studied in the preclinical treatment of pancreatic cancer. However, these studies have required high therapeutic doses [22]. In vivo models of PANC-1 xenografts required repeated daily injections of adenovirus at $10^7$–$10^8$ PFU in order to achieve tumor regression [23]. Herpes simplex viruses G207 and NV1020 and poxvirus-based therapy have also required doses of $10^7$ PFU to cause tumor regression [24, 25]. Typically, in vivo cancer models in athymic mice have required a therapeutic dose of $10^6$–$10^8$ PFU for intravenous delivery [22, 26, 27] and at least $10^7$ PFU for intratumoral delivery [28–30]. In our study, in vivo therapeutic efficacy was noted after a single dose of $10^3$ PFU and the mice displayed no toxicity. These results show that CF33 is more potent than previous generations of oncolytic viruses.

This study displays CF33’s unique ability to rapidly kill pancreatic cancer xenografts after a single intratumoral dose in a rapid fashion. In vivo studies of past generations of vaccinia virus in nude mice have described phases of xenograft regression. Initially, tumors increase in size over the first 2 weeks relative to control. The 3rd week consists of a plateau of tumor growth relative to control. Finally, regression in vaccinia-injected tumor volume is observed beyond 3 weeks [22, 31]. With CF33-Fluc, we demonstrated a truncated timeline. The tumors increased in size relative to control by day 4. The plateau occurred from days 4 to 8 and regression, from day 8, onward. This
low dose model causing rapid tumor regression again points toward CF33 as a promising candidate for clinical application.

We observed spread of virus to distant tumors. To confirm that the abscopal effect was virally induced, we used luciferase imaging and viral titration data. Although our shedding experiments yielded no detectable virus in the blood, we suspect that viral titers were below the limit of detection in the blood of $5 \times 10^2$ PFU/mL. Other modalities of spread are possible; however, low titers detected in other organs would suggest blood-based spreading of virus as seen in other studies [27, 32, 33]. The effect of OV

Fig. 4 CF33 is safe in mice and causes regression of both injected and non-injected distant tumors at a low dose in PANC-1 and MIA PaCa-2 xenograft models. Female athymic nude mice were implanted in the bilateral flank with either PANC-1 or MIA PaCa-2 and a single injection of $10^3$ PFU of CF33 for PANC-1 and $10^5$ PFU for MIA PaCa-2 were administered intra-tumorally in the left tumor. a Percent change in tumor volume in virus-injected PANC-1 tumors (a) and MIA PaCa-2 tumors (b) was significantly lower compared to PBS-injected tumors. c Percent change in the non-injected distant tumors in PANC-1 was significantly smaller with CF33 compared to PBS-injected controls. d Toxicity in PANC-1 xenograft bearing mice was determined by percent change in net body weight. No significant difference in weight change was observed between the virus-treated mice and the PBS-treated mice, suggesting that the dose of virus used in this study is safe in immune-compromised mice (*p < 0.05. **p < 0.01. ***p < 0.0001. ns, not significant. PFU, plaque forming units. PBS, phosphate buffered saline)
therapy on distant tumors has been studied with Newcastle disease virus (NDV) and was shown to be immune-mediated through an increase in tumor-specific CD4(+) and CD8(+) T-cells [34]. T-VEC has also been studied for the tumor regression in injected and non-injected distant tumors, but again, this is thought to be immune-mediated [35]. As such, clinical trials are ongoing which combine T-VEC with immunomodulators [36]. While our study did not analyze the immune-associated abscopal effect, we believe CF33 is highly oncotropic, and can thereby travel to uninjected tumors and cause direct tumor killing. Future studies involving immune-competent mice will add to the data presented in this study.

While there are further immune-mediated mechanisms of distant tumor killing to be investigated, this study provides evidence for the benefits of direct viral spread. Viral spread may be mediated by the secretion of extracellular enveloped virus (EEV), which is surrounded by a host-derived membrane and released from infected cells [7, 37–39]. Point mutations in the glycoprotein coding A34R gene are known to be associated with increased EEV secretion in the vaccinia strain Western Reserve (WR) [40, 41]. However, CF33 contains the wild-type A34R gene and thus the mechanism of increased spread at this time is under investigation. There are benefits to utilizing the efficient spread to other tumors via intratumoral
and viral spread to non-injected tumors following a low investigatory dose. Further studies in immune-competent models ras-  
chimerization and high throughput screening, we have created a novel virus that requires lower doses to treat pancreatic cancer in a preclinical model. CF33-Fluc replication in non-injected, distant tumors halted tumor growth. Further studies in immune-competent models investigating the mechanisms of rapid tumor regression and viral spread to non-injected tumors following a low dose will enhance our understanding of how this novel virus targets and kills pancreatic cancer.

**Abbreviations**
ATCC: American Type Culture Collection; CRT: calreticulin; DAMP: damage-associated molecular pattern; DAPI: 4',6-diamidino-2-phenylindole dihydrochloride; EEV: extracellular enveloped virus; FLuc: firefly luciferase; FOLFIRINOX: folinic acid, fluorouracil, irinotecan hydrochloride, oxaliplatin; H&E: hematoxylin and eosin staining; HMGB1: high-mobility group box 1; ICD: immunogenic cell death; IHC: immunohistochemistry; MOI: multiplicity of infection; OVs: oncolytic viruses; PDAC: pancreatic ductal adenocarcinoma; PFU: plaque-forming unit; PBS: phosphate-buffered saline; TK: thymidine kinase.

**Authors’ contributions**
Conception and Design: MPO, AHC, YF, NGC. Generation, amplification and purification of viruses: JL, NGC. Animal Work: MPO, AHC, SK, SC, JL, AKP, NGC. Analysis: MPO, SK, SC, YW, SGW, YF, NGC. Writing and Review: MPO, AHC, YW, SGW, YF, NGC. Supervision: YF, NGC. All authors read and approved the final manuscript.

**Author details**
1 Department of Surgery, Division of Surgical Oncology, City of Hope National Medical Center, 1500 Duarte Rd, Duarte, CA 91010, USA. 2 Center for Gene Therapy, Department of Hematologic and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA. 3 Gene Editing and Viral Vector Core, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA.

**Acknowledgements and funding**
Research reported in this publication included work performed in the High Throughput Screening Core supported by the National Cancer Institute of the National Institutes of Health under award number P30CA033572. Additional support was provided in part by the Susan Riley Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Competing interests**
The authors declare that they have no competing interests.

**Availability of data and materials**
Data and materials used in this publication can be made available upon request.

**Consent for publication**
All authors have agreed to this publication.

**Ethics approval and consent to participate**
This study did not involve human subjects. All animal studies were conducted under a City of Hope Institutional Animal Care and Use Committee (IACUC)-approved protocol (IACUC #15003).

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Received:** 8 August 2017 **Accepted:** 17 April 2018

**Published online:** 26 April 2018

**References**
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
2. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Beccouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
3. Ehrig K, Kilinc MO, Chen NG, Stritzker J, Buckel L, Zhang Q, Szalay AA. Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68. J Transl Med. 2013;11:79.

4. Haddad D, Zanoni BC, Williams A, Fiering S, Hahne J, Wolf T. Gene therapy with a recombinant vaccinia virus vector for treatment of human cancers. Cancer Gene Ther. 2002;9:433–41.

5. Parato KA, Brentbach C, Le Boeuf F, Wang J, Storbeck C, Illkow C, Diallo JS, Falls T, Burns J, Garcia V, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther. 2012;20:749–58.

6. Mallardo M, Leithe E, Schleich S, Roos N, Doglio L, Krijnse Locker J. Relationship between vaccinia virus intracellular cores, early mRNAs, and DNA replication sites. J Virol. 2002;76:167–83.

7. Kim DH, Wang Y, Liang W, Contag CH, Thorne SH. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. Cancer Res. 2008;68:2071–5.

8. Al Yaghchi C, Zhang Z, Alusi G, Lemoine NR, Wang Y. Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy. 2013;5:1249–58.

9. Hortman RT, Ho SH, Pullen JK, Hunt HD, Cai Z, Pease LR. Gene splicing by overlap extension: Methods Enzymol. 1993;217:270–8.

10. Falkner FG, Moss B. Transient dominant selection of recombinant vaccinia viruses. J Virol. 1990;64:3108–11.

11. Adusumilli PS, Stiles BM, Chan MK, Mullerad M, Eisenberg DP, Ben-Porat L, Huz R, Rutsch VW, Fong Y. Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. J Gene Med. 2006;8:603–15.

12. De Munk J, Binks A, McNeish IA, Aerts JL. Oncolytic virus-induced cell death and immunity: a match made in heaven? J Leukoc Biol. 2017;102:631–43.

13. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinopathologic analysis of 5-year survivors. Ann Surg. 1996;223:273–9.

14. Klear J, Reiser C, Hinz U, Bachmann J, Debus J, Jaeger D, Friess H, Buchler MW. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg. 2007;245:566–72.

15. Teague A, Lim KH, Wang-Gilliam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. Ther Adv Med Oncol. 2015;7:65–84.

16. Choi A, O’Leary M, Fong Y, Chen N. From benchtop to bedside: a review of oncolytic virotherapy. Biomedicines. 2016;4:18.

17. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Cheson D, Delman KA, Spiteri LE, Puzanov I, Agrawala SS, et al. Talimogene laverparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–8.

18. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kim DH. ONXY-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolyis and antitumor efficacy that can be augmented by standard chemotherapy agents. Nat Med. 1997;3:639–45.

19. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature. 1985;317:813–5.

20. Liu BJ, Robinson M, Han ZQ, Branton RH, English C, Ray P, McGrath Y, Thomas SK, Thornton M, Bullcock P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumor properties. Gene Ther. 2003;10:292–303.

21. Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun. 2017;8:14754.

22. Yu YA, Galas SR, Coo Y, Chen N, Zhang Q, Fong Y, Szalay AA. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther. 2009;8:141–51.

23. Motor F, Sunamura M, Ding L, Duda DG, Yoshida Y, Zhang W, Matsuno S, Hamada H. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum Gene Ther. 2000;11:223–35.

24. McAluiffe PF, Jarnagin WR, Johnson P, Delman KA, Fedoroff H, Fong Y. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg. 2000;4:380–8.

25. Tsushima JR, Brait A, Alusi G, Cao F, Gao D, Yu J, Wang P, Yang S, Dong Z, Wang S, et al. Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther. 2009;16:1223–33.

26. Hoffmann E, Weibel S, Szalay AA. Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice. J Transl Med. 2014;12:172.

27. Zeh HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther. 2002;9:1001–12.

28. Vaha-Koskela M, Tahtinen S, Gronberg-Vaha-Koskela S, Taipale K, Saha D, Mensola-Sokkel M, Ahonen M, Rouvinen-Lagerstrom N, Hirvinen M, Veckman V, et al. Overcoming tumor resistance by heterologous adenovirus-poxvirus combination therapy. Mol Ther Oncolytics. 2015;1:14006.

29. Masuelli L, Fantini M, Benvenuto M, Sacchetti P, Rigoni E, Veckman V, et al. Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. J Transl Med. 2014;12:122.

30. Kleinpenner F, Mendel TH, Thoimedelet C, Geist M, Sfornatno N, Koever V, Fahrer C, Schmitt D, Gamant M, Welte W, et al. Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology. 2016;5:1220467.

31. Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM, Szalay AA. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 2007;67:10038–46.

32. Whitman ED, Tsung K, Paxson J, Norton JA. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery. 1994;116:183–8.

33. Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, Aktas WR, Fuerst TR, Lisdon JJ, Patlak M, et al. Host range restriction, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol. 1996;397:9–17.

34. Zamarin D, Holmgard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6:226ra232.

35. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Dietz AB, Peng KW. Mesenchymal stem cell carriers protect oncolytic vaccinia for the treatment of human cancers. Cancer Gene Ther. 2009;8:141–51.

36. Puzanov I, Milhem MR, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorlick KS, Anderson A, Chou J, et al. Talimogene laverparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB–IV melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:5763–71.

37. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, GlaspY, J Whitman E, Harrington K, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:5763–71.

38. Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol. 2002;83:2915–31.

39. Payne LG. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol. 1980;50:89–100.

40. McIntosh AA, Smith GL. Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J Virol. 1996;70:227–81.

41. Blasco R, Sisler JR, Moss B. Dissociation of progeny vaccinia virus from the infected cell. J Virol. 1996;69:5259–66.

42. Dietz AB, Peng KW. Mesenchymal stem cell carriers protect oncolytic vaccinia viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res. 2009;15:7246–55.